According to Sino Biotech's announcement, the controlling shareholder Sino Investment increased its holdings of the company's shares by 2.054.62 million shares from July 17 to 21, 2026, accounting for 0.91% of the total share capital. The cumulative total turnover was 49.259.76 million yuan. It has exceeded the lower limit of the holdings increase plan, and the implementation of the increase plan has been completed. After this equity change, the shareholding ratio of Sano Investment and its co-actors increased from 30.82% to 31.73%, hitting an integer multiple of 1%. This increase in holdings will not lead to changes in the company's controlling shareholders and actual controllers, and does not involve an offer.

According to Sino Biotech's announcement, the controlling shareholder Sino Investment increased its holdings of the company's shares by 2.054.62 million shares from July 17 to 21, 2026, accounting for 0.91% of the total share capital. The cumulative total turnover was 49.259.76 million yuan. It has exceeded the lower limit of the holdings increase plan, and the implementation of the increase plan has been completed. After this equity change, the shareholding ratio of Sano Investment and its co-actors increased from 30.82% to 31.73%, hitting an integer multiple of 1%. This increase in holdings will not lead to changes in the company's controlling shareholders and actual controllers, and does not involve an offer.